PSS World Medical (Nasdaq: PSSI) is expected to report Q2 earnings on Oct. 25. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict PSS World Medical's revenues will compress -17.9% and EPS will decrease -21.6%.

The average estimate for revenue is $428.6 million. On the bottom line, the average EPS estimate is $0.29.

Revenue details
Last quarter, PSS World Medical reported revenue of $409.4 million. GAAP reported sales were 7.6% higher than the prior-year quarter's $380.5 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at $0.18. GAAP EPS of $0.22 for Q1 were 12% lower than the prior-year quarter's $0.25 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 33.3%, 110 basis points better than the prior-year quarter. Operating margin was 5.2%, about the same as the prior-year quarter. Net margin was 2.6%, 110 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $1.72 billion. The average EPS estimate is $1.11.

Investor sentiment
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 62 members out of 74 rating the stock outperform, and 12 members rating it underperform. Among 26 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 22 give PSS World Medical a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PSS World Medical is hold, with an average price target of $21.19.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.